Nanoemulsion vaccines

A nanoemulsion and adjuvant technology, applied in antiviral agents, allergic diseases, antibody medical components, etc.

Active Publication Date: 2012-07-18
RGT UNIV OF MICHIGAN
View PDF59 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Significant problems inherent in existing vaccines include the need for repeated immunizations, and the ineffectiveness of current vaccine delivery systems for a broad spectrum of diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanoemulsion vaccines
  • Nanoemulsion vaccines
  • Nanoemulsion vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0312] Compositions comprising nanoemulsion inactivated respiratory syncytial virus and methods of utilizing the same

[0313] Materials and Methods

[0314] mice. Balb / c mice were purchased from Jackson Laboratories. All animal work was performed in accordance with University of Michigan Committee on Use and Care of Animals policy.

[0315] Viral plaque assay. Right lung lobes from infected mice were harvested and sanded using a mortar and pestle. Samples from lungs were spun 2x, or obtained after incubation with nanoemulsions, and supernatants were serially diluted onto ~90% confluent monolayers of Vero cells. Samples were incubated for 2 hours at 37°C with gentle rotation, then the infected supernatant was removed and replaced with 0.9% methylcellulose. After 5 days of incubation at 37°C, methylcellulose was removed, replaced with methanol, and incubated at -80°C for 1 hour. After methanol removal, samples were stored at -80°C until plaque development. Plaques were d...

Embodiment 2

[0320] Nanoemulsion effectively inactivates RSV

[0321] To test the ability of the emulsion to inactivate RSV, RSV (10 6 Particle forming units (PFU) were incubated with the nanoemulsion at various concentrations (0% - 20%) and for various times (1 hour - 3 hours) (see figure 1 ). The number of infectious virus was determined via plaque assay using Vero cells. Nanoemulsion-incubated virus was used to infect subconfluent Vero cells. RSV plaques were visualized using immunohistochemical techniques. When as little as 1% nanoemulsion was incubated for 3 hours, there was no detection of active virus as assessed by standard plaque assays (see figure 1 ). Thus, the present invention provides nanoemulsions that are effective in completely killing RSV at concentrations of 2% in as little as 1 hour, or as little as 1% in 3 hours. Accordingly, in some embodiments, the present invention provides nanoemulsions that are effective in reducing and / or completely inactivating RSV infec...

Embodiment 3

[0323] Nanoemulsion immunization enhances immunity upon RSV challenge

[0324] It was next determined whether nanoemulsions could be used as immune enhancing agents to induce immune responses important for protection against viral infection. To examine this aspect, an immunization protocol comprising intranasal priming (nanoemulsion (15%)-RSV mixture (total 10 μl, 5 μl / nostril)) or nanoemulsion alone without RSV as a control group. Animals were subsequently challenged with live, infectious RSV at day 56 (8 weeks) and assessed for evidence of protective immunity. One objective is to monitor RSV-specific antibody production during the immunization protocol. Reciprocal titers of RSV-specific antibodies in serum were determined by enzyme-linked immunosorbent assay (ELISA) against RSV protein extracts. Blood was harvested and sera were collected at specific time points post-immunization, including day 0, 1 week, 4 weeks, and 8 weeks (at RSV challenge), and total serum IgG specif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic nanoemulision compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against a pathogenic virus of the paramyxoviridae family (e.g., a Paramyxovirinae virus (e.g., Paramyxovirus, Rubulavirus and / or Morbillivirus) and / or a Pneumovirinae virus (e.g., respiratory syncytial virus))). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Description

[0001] This application claims priority to US Provisional Patent Application Serial No. 61 / 187,529, filed June 16, 2009, which is hereby incorporated by reference in its entirety. field of invention [0002] The present invention provides methods and compositions for immune response stimulation. Specifically, the present invention provides immunogenic compositions and their use to induce Paramyxoviridae ) pathogenic viruses (such as Paramyxovirinae ( Paramyxovirinae ) viruses such as Paramyxovirus ( Paramyxovirus ), mumps virus ( Rubulavirus ) and / or Morbillivirus ( Morbillivirus )) and / or Pneumoviridae ( Pneumovirinae ) virus (e.g. respiratory syncytial virus))) immune response (e.g. immunization (e.g. protective immunity)). The compositions and methods of the invention are especially useful in clinical (eg, therapeutic and preventive medicine (eg, vaccination)) and research applications. Background of the invention [0003] Immunization is a major feature used t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/155
CPCA61K39/155A61K2039/5252A61K39/0008A61K2039/543A61K2039/545A61K2039/55566A61K2039/57C12N2760/18534A61K39/12A61P11/00A61P31/14A61P37/04
Inventor N.W.卢卡茨D.M.林德尔J.R.小巴克
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap